Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of Human Interferon α1b Inhaled Solution in the Treatment of Respiratory Syncytial Virus Lower Respiratory Tract Infection in Children.
NCT06363370 is registered in ClinicalTrials.gov with Kexing Biopharm Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of Human Interferon α1b Inhaled Solution in the Treatment of Respiratory Syncytial Virus Lower Respiratory Tract Infection in Children.
- Lead sponsor
- Kexing Biopharm Co., Ltd.
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- March 27, 2024
- Completion date
- June 30, 2027
- Enrollment
- 322 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.